Tumor lysate, particle only (TLPO) vaccine is under clinical development by Orbis Health Solutions and currently in Phase II for Melanoma. According to GlobalData, Phase II drugs for Melanoma have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tumor lysate, particle only (TLPO) vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tumor lysate, particle only (TLPO) vaccine overview

Cellular immunotherapy is under development for the treatment of solid tumor, non-small cell lung cancer, ovarian cancer and melanoma. The therapy is composed of dendritic cells loaded with autologous tumor lysate packed in yeast cell wall particles. It is a next generation formulation of tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine. It is administered through intradermal route.

Orbis Health Solutions overview

Orbis Health Solutions is a biotechnology company. The company developing transformative medicines that target the body’s immune system and ignite its natural ability to repair and restore health. Orbis Health Solutions is headquartered in Greenville, South Carolina, the US.

For a complete picture of Tumor lysate, particle only (TLPO) vaccine’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.